Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic

Haiden A Huskamp; Alisa B Busch; Lori Uscher-Pines; Michael L Barnett; Lauren Riedel; Ateev Mehrotra

doi:10.1001/jama.2020.21512

Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic

JAMA. 2020 Dec 15;324(23):2440-2442. doi: 10.1001/jama.2020.21512.

Authors

Haiden A Huskamp¹, Alisa B Busch², Lori Uscher-Pines³, Michael L Barnett⁴, Lauren Riedel¹, Ateev Mehrotra¹

Affiliations

¹ Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
² McLean Hospital, Belmont, Massachusetts.
³ RAND Corporation, Arlington, Virginia.
⁴ Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Abstract

This study uses commercial and Medicare Advantage claims data to compare medication fills, outpatient visits, and urine tests for opioid use disorder in January-May 2020 vs 2019.

MeSH terms

Adolescent
Adult
Buprenorphine / therapeutic use*
COVID-19*
Drug Prescriptions / statistics & numerical data*
Drug Utilization / trends
Female
Humans
Insurance Coverage
Male
Medicare
Middle Aged
Narcotic Antagonists / therapeutic use*
Opioid-Related Disorders / drug therapy*
Pandemics*
United States
Young Adult

Substances

Narcotic Antagonists
Buprenorphine

Abstract

MeSH terms

Substances

Grant support